Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: Analysis of 702 patients after 10-year follow-up

Huan Cheng Chang, Chien Lung Chen, Te Li Chiu, Shu I. Chen, Amy Ming Fang Yen, Tony Hsiu Hsi Chen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Few studies have been conducted to investigate the influence of recombinant human erythropoietin (rhEPO) on the long-term prognosis of end-stage renal disease (ESRD).Design: A retrospective cohort study.Setting: The largest regional hospital renowned for haemodialysis in northern Taiwan.Subjects A total of 702 ESRD patients undergoing haemodialysis between 1993 and 2002 were evaluated.Results: The rate of overall use of rhEPO, vitamin D3 or Fe therapy was 62 %. The 10-year survival rate in patients with rhEPO supplementation was statistically more favourable than that in patients without rhEPO (hazard ratio (HR) = 0.38, 95 % CI 0.30, 0.47, P <0.0001). Similar findings were noted for patients receiving vitamin D3 (HR = 0.36, 95 % CI 0.21, 0.64, P = 0.0004) and Fe (HR = 0.45, 95 % CI 0.33, 0.61, P <0.0001). After adjusting for age, education and aetiology, the administration of rhEPO resulted in statistically significant improvements in long-term survival rate either with (HR = 0.30, 95 % CI 0.22, 0.42) or without (HR = 0.48, 95 % CI 0.38, 0.61) combined use of Fe or vitamin D3.Conclusions: We demonstrated a reduction in long-term mortality related to supplementation therapy with rhEPO, vitamin D3 and Fe. The findings provide a justification for the administration of combined supplement therapy in patients undergoing haemodialysis.

Original languageEnglish
Pages (from-to)2410-2415
Number of pages6
JournalPublic Health Nutrition
Volume12
Issue number12
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Cholecalciferol
Erythropoietin
Chronic Kidney Failure
Renal Dialysis
Iron
Survival
Therapeutics
Survival Rate
Taiwan
Cohort Studies
Retrospective Studies
Education
Mortality

Keywords

  • End-stage renal disease
  • Haemodialysis
  • Recombinant human erythropoietin
  • Survival

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Public Health, Environmental and Occupational Health

Cite this

Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis : Analysis of 702 patients after 10-year follow-up. / Chang, Huan Cheng; Chen, Chien Lung; Chiu, Te Li; Chen, Shu I.; Yen, Amy Ming Fang; Chen, Tony Hsiu Hsi.

In: Public Health Nutrition, Vol. 12, No. 12, 2009, p. 2410-2415.

Research output: Contribution to journalArticle

@article{e1091e9569984d418968fdb82677d6ff,
title = "Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: Analysis of 702 patients after 10-year follow-up",
abstract = "Objective: Few studies have been conducted to investigate the influence of recombinant human erythropoietin (rhEPO) on the long-term prognosis of end-stage renal disease (ESRD).Design: A retrospective cohort study.Setting: The largest regional hospital renowned for haemodialysis in northern Taiwan.Subjects A total of 702 ESRD patients undergoing haemodialysis between 1993 and 2002 were evaluated.Results: The rate of overall use of rhEPO, vitamin D3 or Fe therapy was 62 {\%}. The 10-year survival rate in patients with rhEPO supplementation was statistically more favourable than that in patients without rhEPO (hazard ratio (HR) = 0.38, 95 {\%} CI 0.30, 0.47, P <0.0001). Similar findings were noted for patients receiving vitamin D3 (HR = 0.36, 95 {\%} CI 0.21, 0.64, P = 0.0004) and Fe (HR = 0.45, 95 {\%} CI 0.33, 0.61, P <0.0001). After adjusting for age, education and aetiology, the administration of rhEPO resulted in statistically significant improvements in long-term survival rate either with (HR = 0.30, 95 {\%} CI 0.22, 0.42) or without (HR = 0.48, 95 {\%} CI 0.38, 0.61) combined use of Fe or vitamin D3.Conclusions: We demonstrated a reduction in long-term mortality related to supplementation therapy with rhEPO, vitamin D3 and Fe. The findings provide a justification for the administration of combined supplement therapy in patients undergoing haemodialysis.",
keywords = "End-stage renal disease, Haemodialysis, Recombinant human erythropoietin, Survival",
author = "Chang, {Huan Cheng} and Chen, {Chien Lung} and Chiu, {Te Li} and Chen, {Shu I.} and Yen, {Amy Ming Fang} and Chen, {Tony Hsiu Hsi}",
year = "2009",
doi = "10.1017/S1368980009005308",
language = "English",
volume = "12",
pages = "2410--2415",
journal = "Public Health Nutrition",
issn = "1368-9800",
publisher = "Cambridge University Press",
number = "12",

}

TY - JOUR

T1 - Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis

T2 - Analysis of 702 patients after 10-year follow-up

AU - Chang, Huan Cheng

AU - Chen, Chien Lung

AU - Chiu, Te Li

AU - Chen, Shu I.

AU - Yen, Amy Ming Fang

AU - Chen, Tony Hsiu Hsi

PY - 2009

Y1 - 2009

N2 - Objective: Few studies have been conducted to investigate the influence of recombinant human erythropoietin (rhEPO) on the long-term prognosis of end-stage renal disease (ESRD).Design: A retrospective cohort study.Setting: The largest regional hospital renowned for haemodialysis in northern Taiwan.Subjects A total of 702 ESRD patients undergoing haemodialysis between 1993 and 2002 were evaluated.Results: The rate of overall use of rhEPO, vitamin D3 or Fe therapy was 62 %. The 10-year survival rate in patients with rhEPO supplementation was statistically more favourable than that in patients without rhEPO (hazard ratio (HR) = 0.38, 95 % CI 0.30, 0.47, P <0.0001). Similar findings were noted for patients receiving vitamin D3 (HR = 0.36, 95 % CI 0.21, 0.64, P = 0.0004) and Fe (HR = 0.45, 95 % CI 0.33, 0.61, P <0.0001). After adjusting for age, education and aetiology, the administration of rhEPO resulted in statistically significant improvements in long-term survival rate either with (HR = 0.30, 95 % CI 0.22, 0.42) or without (HR = 0.48, 95 % CI 0.38, 0.61) combined use of Fe or vitamin D3.Conclusions: We demonstrated a reduction in long-term mortality related to supplementation therapy with rhEPO, vitamin D3 and Fe. The findings provide a justification for the administration of combined supplement therapy in patients undergoing haemodialysis.

AB - Objective: Few studies have been conducted to investigate the influence of recombinant human erythropoietin (rhEPO) on the long-term prognosis of end-stage renal disease (ESRD).Design: A retrospective cohort study.Setting: The largest regional hospital renowned for haemodialysis in northern Taiwan.Subjects A total of 702 ESRD patients undergoing haemodialysis between 1993 and 2002 were evaluated.Results: The rate of overall use of rhEPO, vitamin D3 or Fe therapy was 62 %. The 10-year survival rate in patients with rhEPO supplementation was statistically more favourable than that in patients without rhEPO (hazard ratio (HR) = 0.38, 95 % CI 0.30, 0.47, P <0.0001). Similar findings were noted for patients receiving vitamin D3 (HR = 0.36, 95 % CI 0.21, 0.64, P = 0.0004) and Fe (HR = 0.45, 95 % CI 0.33, 0.61, P <0.0001). After adjusting for age, education and aetiology, the administration of rhEPO resulted in statistically significant improvements in long-term survival rate either with (HR = 0.30, 95 % CI 0.22, 0.42) or without (HR = 0.48, 95 % CI 0.38, 0.61) combined use of Fe or vitamin D3.Conclusions: We demonstrated a reduction in long-term mortality related to supplementation therapy with rhEPO, vitamin D3 and Fe. The findings provide a justification for the administration of combined supplement therapy in patients undergoing haemodialysis.

KW - End-stage renal disease

KW - Haemodialysis

KW - Recombinant human erythropoietin

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=74949106869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949106869&partnerID=8YFLogxK

U2 - 10.1017/S1368980009005308

DO - 10.1017/S1368980009005308

M3 - Article

C2 - 19344540

AN - SCOPUS:74949106869

VL - 12

SP - 2410

EP - 2415

JO - Public Health Nutrition

JF - Public Health Nutrition

SN - 1368-9800

IS - 12

ER -